Luminex Corporation (LMNX): Price and Financial Metrics


Luminex Corporation (LMNX)

Today's Latest Price: $24.28 USD

0.55 (2.32%)

Updated Dec 1 4:00pm

Add LMNX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

LMNX Stock Summary

  • LMNX's current price/earnings ratio is 61.19, which is higher than 85.27% of US stocks with positive earnings.
  • With a year-over-year growth in debt of 1,069.73%, Luminex Corp's debt growth rate surpasses 98.13% of about US stocks.
  • Over the past twelve months, LMNX has reported earnings growth of -354.42%, putting it ahead of only 5.62% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Luminex Corp are INVE, CAMT, OSS, ATEN, and MITK.
  • Visit LMNX's SEC page to see the company's official filings. To visit the company's web site, go to www.luminexcorp.com.

LMNX Stock Price Chart Interactive Chart >

Price chart for LMNX

LMNX Price/Volume Stats

Current price $24.28 52-week high $41.69
Prev. close $23.73 52-week low $20.29
Day low $23.61 Volume 727,600
Day high $24.54 Avg. volume 639,646
50-day MA $23.24 Dividend yield 1.52%
200-day MA $28.58 Market Cap 1.13B

Luminex Corporation (LMNX) Company Bio


Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics and life sciences industries worldwide. The company was founded in 1995 and is based in Austin, Texas.

LMNX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$24.28$5.1 -77%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Luminex Corp. To summarize, we found that Luminex Corp ranked in the 18th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Luminex Corp, consider:

  • Its compound free cash flow growth rate, as measured over the past 5.7 years, is -0.01% -- higher than only 22.87% of stocks in our DCF forecasting set.
  • The company has produced more trailing twelve month cash flow than merely 23.4% of its sector Healthcare.
  • Luminex Corp's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 24.56% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-77%
1%-77%
2%-77%
3%-77%
4%-76%
5%-76%

Want more companies with a valuation profile/forecast similar to that of Luminex Corp? See CNMD, CNC, MOH, NUVA, and GMED.


LMNX Latest News Stream


Event/Time News Detail
Loading, please wait...

LMNX Latest Social Stream


Loading social stream, please wait...

View Full LMNX Social Stream

Latest LMNX News From Around the Web

Below are the latest news stories about Luminex Corp that investors may wish to consider to help them evaluate LMNX as an investment opportunity.

Luminex Receives BARDA Award to Support 510(k) Filing for NxTAG Respiratory Pathogen Panel That Includes SARS-CoV-2

AUSTIN, Texas, Sept. 24, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received a $5,389,813 award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response…

PR Newswire | September 24, 2020

Luminex Receives BARDA Award to Support Enhancement of COVID-19 Multiplex Antibody Test

AUSTIN, Texas, Sept. 23, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received an award of $683,500 from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response…

PR Newswire | September 23, 2020

Luminex Home Décor & Fragrance Hires Seasoned Consumer Products CEO

CINCINNATI--(BUSINESS WIRE)--Luminex Announces Scott Meader as CEO

Business Wire | August 27, 2020

Luminex Announces Graduation to OTCQX Best Market in the U.S. under the Symbol LUMIF

VANCOUVER, BC, Aug. 18, 2020 /PRNewswire/ - Luminex Resources Corp. (TSXV: LR) (OTCQX: LUMIF) (the "Company" or "Luminex") is pleased to announce that its common shares are now trading on the OTCQX Best Market, a U.S. market operated by OTC Markets Group in New York, under the symbol…

PR Newswire | August 18, 2020

Global Genomics Market Outlook 2020-2025; Dominated by Illumina, Thermo Fisher Scientific, Agilent Technologies, Luminex Corporation and Myriad Genetics - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Genomics Market - Growth, Trends, and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering. The Global Genomics Market is anticipated to grow at a CAGR of 9.3% during the forecast period. The major factors attributing to the growth of the genomics market are growing government support and increased number of genomics studies, declining sequencing cost, increased genomics applications. The genomics market is geared to exponential growth

Business Wire | August 13, 2020

Read More 'LMNX' Stories Here

LMNX Price Returns

1-mo 8.93%
3-mo -2.45%
6-mo -19.63%
1-year 19.92%
3-year 18.49%
5-year 17.82%
YTD 5.86%
2019 1.58%
2018 18.40%
2017 -1.42%
2016 -5.42%
2015 14.02%

LMNX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full LMNX Dividend History

Continue Researching LMNX

Want to see what other sources are saying about Luminex Corp's financials and stock price? Try the links below:

Luminex Corp (LMNX) Stock Price | Nasdaq
Luminex Corp (LMNX) Stock Quote, History and News - Yahoo Finance
Luminex Corp (LMNX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9218 seconds.